Looking to buy FOX-04 for laboratory senescence research? FOX-04, short for FOXO4 D-Retro-Inverso, is a synthetic research peptide designed to interfere with the interaction between the FOXO4 transcription factor and the p53 tumour-suppressor protein.<\/p>\n
This protein interaction has been investigated for its role in supporting the survival of certain senescent cells. Senescent cells have permanently stopped dividing but may remain metabolically active and release signalling molecules associated with tissue ageing and inflammatory processes.<\/p>\n
In a landmark 2017 preclinical study led by researchers affiliated with Erasmus University Medical Center Rotterdam, FOXO4-DRI preferentially reduced the viability of senescent cells by disrupting FOXO4\u2013p53 binding. This promoted the relocation of active p53 and initiated apoptosis in the senescent cells studied. Control cells were less affected under the specific experimental conditions used.<\/p>\n
Peptides Divas supplies FOXO4-DRI in a 10 mg format as a stable lyophilised powder. Each batch is accompanied by batch-specific analytical documentation.<\/p>\n
Dit product is uitsluitend bestemd voor laboratoriumonderzoek. Het is niet bestemd voor gebruik door mensen of dieren.<\/strong><\/p>\n FOXO4-DRI is studied as an experimental senolytic peptide. In preclinical cell models, it has been shown to compete with FOXO4 for p53 binding, promoting p53 relocation from the nucleus and activating apoptosis-associated pathways in certain senescent cells.<\/p>\n These findings are model-dependent and should not be interpreted as evidence that FOXO4-DRI targets every type of senescent cell.<\/p>\n FOXO4 is een transcriptiefactor die betrokken is bij cellulaire stressreacties, homeostase en celbestemmingsregulatie. In de onderzochte modellen van senescente cellen hielp FOXO4 p53 in de celkern vast te houden. FOXO4-DRI is ontworpen om deze interactie te verstoren en p53 uit deze nucleaire complexen vrij te maken.<\/p>\n In muismodellen werd experimentele toediening van FOXO4-DRI geassocieerd met verbeteringen in bepaalde parameters van weefselhomeostase, waaronder markers gerelateerd aan nierfunctie, vachtdichtheid en fysieke activiteit. Deze resultaten werden verkregen bij dieren en kunnen niet rechtstreeks worden ge\u00ebxtrapoleerd naar mensen.<\/p>\n FOXO4-DRI uses a D-retro-inverso design in which D-amino acids are arranged in reverse sequence order. This design is commonly investigated as a method of preserving functional side-chain orientation while increasing resistance to proteolytic degradation compared with corresponding conventional L-peptides.<\/p>\n The exact stability and performance of an individual batch depend on its composition, handling and experimental conditions.<\/p>\n Some senescent cells produce a collection of inflammatory cytokines, growth factors and proteases known as the senescence-associated secretory phenotype, or SASP.<\/p>\n By investigating the selective removal of senescent cells, researchers may study whether FOXO4-DRI influences SASP-related signalling and inflammatory processes in controlled experimental models. This remains a preclinical research field and is not an established clinical application.<\/p>\n Bij elke batch FOXO4-DRI wordt een analysecertificaat meegeleverd. Afhankelijk van de beschikbare batchdocumentatie kan de analyse het volgende omvatten:<\/p>\n Raadpleeg altijd het analysecertificaat voor de exacte specificaties en analyseresultaten van de geleverde partij.<\/p>\n FOXO4-DRI 10 mg wordt uitsluitend geleverd voor gecontroleerd wetenschappelijk en laboratoriumonderzoek. Het is geen geneesmiddel, voedingssupplement of cosmetisch product en is niet goedgekeurd voor menselijke consumptie, therapeutische toepassingen, klinisch gebruik of diergeneeskundig gebruik.<\/p>","protected":false},"excerpt":{"rendered":" Looking to buy FOXO4-DRI for laboratory senescence research? FOXO4-DRI, short for FOXO4 D-Retro-Inverso, is a synthetic research peptide designed to interfere with the interaction between the FOXO4 transcription factor and the p53 tumour-suppressor protein.<\/p>\n This protein interaction has been investigated for its role in supporting the survival of certain senescent cells. Senescent cells have permanently stopped dividing but may remain metabolically active and release signalling molecules associated with tissue ageing and inflammatory processes.<\/p>\n In a landmark 2017 preclinical study led by researchers affiliated with Erasmus University Medical Center Rotterdam, FOXO4-DRI preferentially reduced the viability of senescent cells by disrupting FOXO4\u2013p53 binding. This promoted the relocation of active p53 and initiated apoptosis in the senescent cells studied. Control cells were less affected under the specific experimental conditions used.<\/p>\n Peptides Divas supplies FOXO4-DRI in a 10 mg format as a stable lyophilised powder. Each batch is accompanied by batch-specific analytical documentation.<\/p>\n Dit product is uitsluitend bestemd voor laboratoriumonderzoek. Het is niet bestemd voor gebruik door mensen of dieren.<\/strong><\/p>","protected":false},"featured_media":741,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"nf_dc_page":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0},"product_brand":[],"product_cat":[34],"product_tag":[46],"class_list":["post-740","product","type-product","status-publish","has-post-thumbnail","product_cat-recovery-repair","product_tag-10-mg","first","instock","shipping-taxable","purchasable","product-type-simple"],"acf":[],"yoast_head":"\nFOXO4-DRI Productspecificaties<\/h2>\n
\n\n
\n \nSpecificatie<\/th>\n Details<\/th>\n<\/tr>\n<\/thead>\n \n Productnaam<\/td>\n FOXO4-DRI<\/td>\n<\/tr>\n \n Volledige naam<\/td>\n FOXO4 D-Retro-Inverso peptide<\/td>\n<\/tr>\n \n Hoeveelheid<\/td>\n 10 mg per flacon<\/td>\n<\/tr>\n \n Onderzoekscategorie<\/td>\n Cellulaire veroudering en senolytisch onderzoek<\/td>\n<\/tr>\n \n Onderzocht mechanisme<\/td>\n Verstoring van de FOXO4\u2013p53-eiwitinteractie<\/td>\n<\/tr>\n \n Zuiverheid<\/td>\n \u226599,5% volgens HPLC<\/td>\n<\/tr>\n \n Formulier<\/td>\n Gevriesdroogd poeder<\/td>\n<\/tr>\n \n Peptideontwerp<\/td>\n D-retro-inverso structuur<\/td>\n<\/tr>\n \n Opslag<\/td>\n Bewaren bij -20 \u00b0C, beschermd tegen licht en vocht.<\/td>\n<\/tr>\n \n Documentatie<\/td>\n Batchspecifiek analysecertificaat<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Relevantie van wetenschappelijk onderzoek<\/h2>\n
Onderzoek naar senescente cellen<\/h3>\n
FOXO4\u2013p53-interactie<\/h3>\n
Onderzoek naar verouderingsbiologie<\/h3>\n
D-Retro-Inverso Peptide-ontwerp<\/h3>\n
SASP en ontstekingsonderzoek<\/h3>\n
Kwaliteitsborging<\/h2>\n
\n
Alleen voor onderzoeksdoeleinden<\/h2>\n
FOXO4-DRI 10 mg \u2013 Senolytic Research Peptide<\/h1>\n